VIS-954 by Visterra for Anti-Neutrophil Cytoplasmic Antibody

VIS-954 is under clinical development by Visterra and currently in Phase I for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis).

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Massachusetts , United States , , Globaldata Pharmaceutical Intelligence Center , Otsuka Holdings Co Ltd , Pharmaceutical Intelligence ,